Rituximab therapy for juvenile-onset systemic lupus erythematosus

Rituximab (RTX), an anti-CD20 monoclonal antibody, has been proposed for use in the therapy of systemic lupus erythematosus (SLE). We present the initial long-term experience of the safety and efficacy of rituximab for treatment of SLE in children. Eighteen patients (mean age 14 ± 3 years) with seve...

Descripción completa

Detalles Bibliográficos
Autores principales: Nwobi, Obioma, Abitbol, Carolyn L., Chandar, Jayanthi, Seeherunvong, Wacharee, Zilleruelo, Gastón
Formato: Texto
Lenguaje:English
Publicado: Springer-Verlag 2007
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214826/
https://www.ncbi.nlm.nih.gov/pubmed/18097688
http://dx.doi.org/10.1007/s00467-007-0694-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2214826/
https://www.ncbi.nlm.nih.gov/pubmed/18097688
http://dx.doi.org/10.1007/s00467-007-0694-9

Ejemplares similares